1-855-378-42281-855-378-4228
One of the out-patient rehabilitation options for individuals in Vermillion who are battling with opioid abuse and addiction is opioid maintenance therapy. Licensed facilities and doctors are certified to give specific meds to opioid addicted people, many that are opioids themselves and are addiction. With low enough amounts however, the user does not experience being high but also doesn't experience intense cravings and isn't experiencing opioid withdrawal. Methadone is the first drug used for this reason, but there are other choices to choose from.
Methadone is an opiate and is meant to be taken at an outpatient medical center licensed to administer the drug, which is taken daily as a pill or liquid. The price of the drug is about one hundred and fifty dolloars a month. Buprenorphine is also an opioid based drug, and is in pill form often taken one day on, one day off. But different from Methadone which can only be administered in highly well-regulated clinics, Buprenorphine can be prescribed and administered in doctor's offices. The price monthly of buprenorphine is approximately $300.00 monthly for the generic version of the drug. There is also a type of buprenorphine that contains the ingredient naloxone, which is a drug which reverses the effects of opioids. Someone consuming this formulation, also known as Suboxone, would find it harder to feel high from opioids if they relapsed while taking the drug. It is also taken every day, and costs around $450 monthly. Naltrexone is an additional medication used in opioid maintenance therapy, but unlike the other drugs mentioned it's an opioid blocker and isn't an opioid. There is an option to take this drug as a monthly injection, which is called Vivitrol. As an opioid blocker, it prevents an individual from experience being high from opioids, and in turn lowers the risk associated with relapse. This daily injection costs in the range of $1000 to $1200 monthly.
For All Drug and Alcohol Rehabilitation Facilities In Vermillion, Click Here.
